Jeanette Mucha, BS '93
SciBac makes evolutionary live biotherapeutics that replace antibiotics. We are a platform driven company that uses a patent-pending natural method to transfer beneficial traits from one probiotic microbe to another. Our first product, Diffikil, is a first line treatment directed towards Clostridium difficile infection which affects half a million Americans per year. Diffikil is composed of three beneficial species that attack the pathogen on three fronts. Diffikil prevents attachment of C. difficile to the colon, directly kills C. difficle with multiple bacteriocins, and neutralizes C. difficile toxin with several anti-toxins.
Alumni Discount: We are an early start-up with our first product is in animal studies and currently unavailable to the public. Please stay tuned to our progress!
Web:
http://scibac.comEmail:
jeanette.mucha@scibac.com Phone: 650-689-5343
Address: 1828 El Camino Real, Ste. 704, Burlingame, CA 94010